Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells

Biochemical Pharmacology

Volumn 57, Issue 4, 1999, Pages 347-353

  Li, Qingdi ^a   Tsang, Byron ^a   Bostick Bruton, Frieda ^a   Reed, Eddie ^a  

^a Devmtl Therapeut Dept Med B   (United States)

Author keywords

Cisplatin; Cyclosporine; ERCC 1; Herbimycin A; Ovarian cancer; Phorbol ester

Indexed keywords

CISPLATIN; CYCLOSPORIN A; HERBIMYCIN A; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; EXCISION REPAIR; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NORTHERN BLOTTING; OVARY CARCINOMA; PRIORITY JOURNAL; RNA SYNTHESIS;

BENZOQUINONES; CISPLATIN; CYCLOSPORINE; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; GENE EXPRESSION REGULATION; HUMANS; LACTAMS, MACROCYCLIC; PROTEIN BIOSYNTHESIS; PROTEINS; QUINONES; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED;

EID: 0032946612     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00291-3     Document Type: Article

References (45)

1. Reed E. The chemotherapy of ovarian cancer. PPO Update. 10:1996;1-12.
2. Reed E, Dabholkar M and Chabner BA, Platinum analogues. In: Cancer Chemotherapy (Eds. Chabner BA and Longo DL), 2nd Edn, pp. 357-378. Lippincott-Raven Publishers, Philadelphia, 1996.
3. Reed E, Platinum analogs. In: Cancer - Principles & Practice of Oncology (Eds. DeVita VT, Hellman S and Rosenberg SA), 4th Edn, pp. 390-400. J. B. Lippincott, Philadelphia, 1993.
4. Young RC, Perez CA and Hoskins WJ, Cancer of the ovary. In: Cancer - Principles & Practice of Oncology (Eds. DeVita VT, Hellman S and Rosenberg SA), 4th Edn, pp. 1245-1252. J. B. Lippincott, Philadelphia, 1993.
5. Lepre C.A., Lippard S.J. Interaction of platinum antitumor compounds with DNA. Nucleic Acids Mol Biol. 4:1990;9-38.
6. Parker R.J., Eastman A., Bostick-Bruton F., Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced DNA repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest. 87:1991;773-777.
7. Dabholkar M., Reed E. Cisplatin. Cancer Chemother Biol Response Modif. 16:1996;88-110.
8. Gosland M., Lum B., Schimmelpfennig J., Baker J., Doukas M. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy. 16:1996;16-39.
9. Chen G., Hutter K.J., Zeller W.J. Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Cell Biol Toxicol. 11:1995;273-281.
10. Godwin A., Meister A., O'Dwyer P., Huang C., Hamilton T., Anderson M. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 89:1992;3070-3074.
11. Hamaguchi K., Godwin A.K., Yakushiji M., O'Dwyer P.J., Ozols R.F., Hamilton T.C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 53:1993;5225-5232.
12. Masuda H., Ozols R.F., Lai G.-M., Fojo A., Rothenberg M., Hamilton T.C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 48:1988;5713-5716.
13. Lee K.B., Parker R.J., Bohr V., Cornelison T., Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis. 14:1993;2177-2180.
14. Sancar A. Mechanisms of DNA excision repair. Science. 266:1994;1954-1956.
15. Zhen W., Link C.J. Jr, O'Connor P.M., Reed E., Parker R., Howell S.B., Bohr V.A. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol. 12:1992;3689-3698.
16. Jones J.C., Zhen W., Reed E., Parker R.J., Sancar A., Bohr V.A. Preferential DNA repair of cisplatinum lesions in active genes in CHO cells. J Biol Chem. 266:1991;7101-7107.
17. Moggs J.G., Yarema K.J., Essigmann J.M., Wood R.D. Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct. J Biol Chem. 271:1996;7177-7186.
18. Calsou P., Barret J.-M., Cros S., Salles B. DNA excision-repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin. Eur J Biochem. 211:1993;403-409.
19. Aboussekhra A. Nucleotide excision repair in vitro and in normal/abnormal human cells. Cell Pharmacol. 3:1996;221-224.
20. Friedberg EC, Walker GC and Siede W, DNA Repair and Mutagenesis, pp. 317-326. ASM Press, Washington, DC, 1995.
21. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., Reed E. Messenger RNA levels of XPA and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. 94:1994;703-708.
22. Taverna P., Hansson J., Scanlon K.J., Hill B.T. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis. 15:1994;2053-2056.
23. Dabholkar M., Bostick-Bruton F., Weber C., Bohr V., Egwuagu C., Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst. 84:1992;1512-1517.
24. Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., Knutsen T., McKoy W.M., Young R.C., Ozols R.F. Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:1987;414-418.
25. Saotome K., Morita H., Umeda M. Cytotoxicity test with simplified crystal violet staining method using microtiter plates and its application to injection drugs. Toxicol In Vitro. 3:1989;317-321.
26. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
27. Sambrook J, Fritsch EF and Maniatis T, Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
28. Manetta A., Boyle J., Berman M.L., DiSaia P.J. Cyclosporine enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. Cancer. 73:1994;196-199.
29. Kashani-Sabet M., Wang W., Scanlon K.J. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem. 265:1990;11285-11288.
30. Rabo Y.B., Shoshan M.C., Linder S., Hansson J. Different mechanisms are responsible for c-jun mRNA induction by cisplatin and ultraviolet light. Int J Cancer. 65:1996;821-826.
31. Huang T.-S., Lee S.-C., Lin J.-K. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA. 88:1991;5292-5296.
32. Park C.H., Bessho T., Matsunaga T., Sancar A. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem. 270:1995;22657-22660.
33. Biggerstaff M., Szymkowski D.E., Wood R.D. Co-correction of the ERCC1, ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro. EMBO J. 12:1993;3685-3692.
34. van Vuuren A.J., Appeldoorn E., Odijk H., Yasui A., Jaspers N.G.J., Bootsma D., Hoeijmakers J.H.J. Evidence for a repair enzyme complex involving ERCC1 and complementing activities of ERCC4, ERCC11 and xeroderma pigmentosum group F. EMBO J. 12:1993;3693-3701.
35. van Duin M., Koken M.H.M., van den Tol J., ten Dijke P., Odijk H., Westerveld A., Bootsma D., Hoeijmakers J.H.J. Genomic characterization of the human DNA excision repair gene ERCC-1. Nucleic Acids Res. 15:1987;9195-9213.
36. Devary Y., Gottlieb R.A., Lau L.F., Karin M. Rapid and preferential activation of the c-jun gene during the mammalian UV response. Mol Cell Biol. 11:1991;2804-2811.
37. Boyle W.J., Smeal T., Defize L.H.K. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA binding activity. Cell. 64:1991;573-584.
38. Ofir R., Dwarki V.J., Rashid D., Verma I.M. Phosphorylation of the C terminus of Fos protein is required for transcriptional transrepression of the c-fos promoter. Nature. 348:1990;80-82.
39. Auwerx J., Sassone-Corsi P. IP-1: A dominant inhibitor of Fos/Jun whose activity is modulated by phosphorylation. Cell. 64:1991;983-993.
40. Angel P., Imagawa M., Chiu R. Phorbol ester inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell. 49:1987;729-739.
41. Cooper GM. Oncogenes, 2nd Edn, pp. 260-296. Jones & Bartlett Publishers, Boston, 1995.
42. Scanlon K.J., Wang W.Z., Han H. Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells. Cancer Treat Rev. 17:(Suppl A):1990;27-35.
43. Baldary C.T., Macchia G., Heguy A., Melli M., Telford J.L. Cyclosporin A blocks calcium-dependent pathways of gene activation. J Biol Chem. 266:1991;19103-19108.
44. Mattila P.S., Ullman K.S., Fiering S. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. EMBO J. 9:1990;4425-4433.
45. Flanagan W.M., Corthesy B., Bram R.J., Crabtree G.R. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature. 352:1991;803-807.